Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

NG2/CSPG4 in glioblastoma: about flexibility.

Finocchiaro G, Pellegatta S.

Neuro Oncol. 2019 Mar 28. pii: noz055. doi: 10.1093/neuonc/noz055. [Epub ahead of print] No abstract available.

PMID:
30918960
2.

Diversified expression of NG2/CSPG4 isoforms in glioblastoma and human foetal brain identifies pericyte subsets.

Girolamo F, Dallatomasina A, Rizzi M, Errede M, Wälchli T, Mucignat MT, Frei K, Roncali L, Perris R, Virgintino D.

PLoS One. 2013 Dec 26;8(12):e84883. doi: 10.1371/journal.pone.0084883. eCollection 2013. Erratum in: PLoS One. 2014;9(4):e95120.

3.

Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma.

Tsidulko AY, Kazanskaya GM, Kostromskaya DV, Aidagulova SV, Kiselev RS, Volkov AM, Kobozev VV, Gaitan AS, Krivoshapkin AL, Grigorieva EV.

Tumour Biol. 2017 Sep;39(9):1010428317724282. doi: 10.1177/1010428317724282.

PMID:
28945172
4.

Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.

Poli A, Wang J, Domingues O, Planagumà J, Yan T, Rygh CB, Skaftnesmo KO, Thorsen F, McCormack E, Hentges F, Pedersen PH, Zimmer J, Enger PØ, Chekenya M.

Oncotarget. 2013 Sep;4(9):1527-46.

5.

The Significance of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Human Gliomas.

Schiffer D, Mellai M, Boldorini R, Bisogno I, Grifoni S, Corona C, Bertero L, Cassoni P, Casalone C, Annovazzi L.

Int J Mol Sci. 2018 Sep 12;19(9). pii: E2724. doi: 10.3390/ijms19092724. Review.

6.

Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage.

Hsu SC, Nadesan P, Puviindran V, Stallcup WB, Kirsch DG, Alman BA.

J Biol Chem. 2018 Feb 16;293(7):2466-2475. doi: 10.1074/jbc.M117.805051. Epub 2017 Dec 1.

7.

Functional roles of CSPG4/NG2 in chondrosarcoma.

Jamil NS, Azfer A, Worrell H, Salter DM.

Int J Exp Pathol. 2016 Apr;97(2):178-86. doi: 10.1111/iep.12189. Epub 2016 Jun 12.

8.

Theranostic impact of NG2/CSPG4 proteoglycan in cancer.

Nicolosi PA, Dallatomasina A, Perris R.

Theranostics. 2015 Feb 15;5(5):530-44. doi: 10.7150/thno.10824. eCollection 2015. Review.

9.

Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma.

Wang J, Svendsen A, Kmiecik J, Immervoll H, Skaftnesmo KO, Planagumà J, Reed RK, Bjerkvig R, Miletic H, Enger PØ, Rygh CB, Chekenya M.

PLoS One. 2011;6(7):e23062. doi: 10.1371/journal.pone.0023062. Epub 2011 Jul 29.

10.

Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma.

Svendsen A, Verhoeff JJ, Immervoll H, Brøgger JC, Kmiecik J, Poli A, Netland IA, Prestegarden L, Planagumà J, Torsvik A, Kjersem AB, Sakariassen PØ, Heggdal JI, Van Furth WR, Bjerkvig R, Lund-Johansen M, Enger PØ, Felsberg J, Brons NH, Tronstad KJ, Waha A, Chekenya M.

Acta Neuropathol. 2011 Oct;122(4):495-510. doi: 10.1007/s00401-011-0867-2. Epub 2011 Aug 24.

11.

The regulatory mechanisms of NG2/CSPG4 expression.

Ampofo E, Schmitt BM, Menger MD, Laschke MW.

Cell Mol Biol Lett. 2017 Feb 28;22:4. doi: 10.1186/s11658-017-0035-3. eCollection 2017. Review.

12.

Combining NK cells and mAb9.2.27 to combat NG2-dependent and anti-inflammatory signals in glioblastoma.

Kmiecik J, Gras Navarro A, Poli A, Planagumà JP, Zimmer J, Chekenya M.

Oncoimmunology. 2014 Jan 1;3(1):e27185.

13.

Structural deciphering of the NG2/CSPG4 proteoglycan multifunctionality.

Tamburini E, Dallatomasina A, Quartararo J, Cortelazzi B, Mangieri D, Lazzaretti M, Perris R.

FASEB J. 2019 Mar;33(3):3112-3128. doi: 10.1096/fj.201801670R. Epub 2018 Dec 14.

PMID:
30550356
14.

NG2/CSPG4 and progranulin in the posttraumatic glial scar.

Schäfer MKE, Tegeder I.

Matrix Biol. 2018 Aug;68-69:571-588. doi: 10.1016/j.matbio.2017.10.002. Epub 2017 Oct 17. Review.

PMID:
29054751
15.

Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.

Beard RE, Zheng Z, Lagisetty KH, Burns WR, Tran E, Hewitt SM, Abate-Daga D, Rosati SF, Fine HA, Ferrone S, Rosenberg SA, Morgan RA.

J Immunother Cancer. 2014 Aug 19;2:25. doi: 10.1186/2051-1426-2-25. eCollection 2014.

16.

NG2/CSPG4-collagen type VI interplays putatively involved in the microenvironmental control of tumour engraftment and local expansion.

Cattaruzza S, Nicolosi PA, Braghetta P, Pazzaglia L, Benassi MS, Picci P, Lacrima K, Zanocco D, Rizzo E, Stallcup WB, Colombatti A, Perris R.

J Mol Cell Biol. 2013 Jun;5(3):176-93. doi: 10.1093/jmcb/mjt010. Epub 2013 Apr 3.

17.

Mesenchymal Tumors Can Derive from Ng2/Cspg4-Expressing Pericytes with β-Catenin Modulating the Neoplastic Phenotype.

Sato S, Tang YJ, Wei Q, Hirata M, Weng A, Han I, Okawa A, Takeda S, Whetstone H, Nadesan P, Kirsch DG, Wunder JS, Alman BA.

Cell Rep. 2016 Jul 26;16(4):917-927. doi: 10.1016/j.celrep.2016.06.058. Epub 2016 Jul 14.

18.

Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins.

Eng MS, Kaur J, Prasmickaite L, Engesæter BØ, Weyergang A, Skarpen E, Berg K, Rosenblum MG, Mælandsmo GM, Høgset A, Ferrone S, Selbo PK.

Photochem Photobiol Sci. 2018 May 16;17(5):539-551. doi: 10.1039/C7PP00358G.

PMID:
29565434
19.

Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types.

Ilieva KM, Cheung A, Mele S, Chiaruttini G, Crescioli S, Griffin M, Nakamura M, Spicer JF, Tsoka S, Lacy KE, Tutt ANJ, Karagiannis SN.

Front Immunol. 2018 Jan 10;8:1911. doi: 10.3389/fimmu.2017.01911. eCollection 2017. Review.

20.

Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy.

Pellegatta S, Savoldo B, Di Ianni N, Corbetta C, Chen Y, Patané M, Sun C, Pollo B, Ferrone S, DiMeco F, Finocchiaro G, Dotti G.

Sci Transl Med. 2018 Feb 28;10(430). pii: eaao2731. doi: 10.1126/scitranslmed.aao2731. Erratum in: Sci Transl Med. 2018 Apr 4;10 (435):.

PMID:
29491184

Supplemental Content

Support Center